Most here have fairly lofty expectations on where this company can head over the next 6-7 months in the lead up to commercialization, warranted expectations from what I have seen in this type of stock over the last few years. Patience and belief can be somewhat hard to maintain when there is little interest in a stock so at times it is necessary to step back and look at the bigger picture and ask if the expectations are realistic.
-ePat has a pain assessment tool which has been proven to be superior to the current assessment methods
-Capital management is exemplary with cash burn of only ~500k/quarter (avg)
-Strong partnerships have been built with potential customers having early stage buy in thurough trial inclusion
-CSIRO, IBM and nViso have displayed a high level of support in publishing the success's to date of their collaborative work with ePat, it seems that ePat will be something of a poster child for them to prove the ability of their respective platforms to penetrate the facial recognition and telehealth markets. nViso under the service agreement have agreed to take a portion of google play store revenue in lieu of a portion of payment for the app development.
- Commercialization, planned by Sep-November 2017 is likely to initially leverage existing relationships in aged care allowing for a rapid monetization approach.
The if we consider the guy at the helm
Versatile with proven strategic, general management, commercial, organizational and interpersonal skills. Philip works with CEOs and senior executives in the areas of business and commercialization strategies, market development programs and building global industry partnerships for distribution and strategic alliances. Philip has been based in Sydney since 2001 and has held senior business leadership positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer relationships in each sector. Roles in Australia have included VP Global Marketing at Cochlear, General Manager with Roche Diagnostics and Bio-Rad Laboratories and CEO of Applied Physiology, an Australian start up company in the intensive care monitoring sector. Philip’s earlier experience was gained in Europe with market leaders including IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and was promoted to Global Marketing Director in the Diabetes Care business unit based in Mannheim, Germany with a business responsibility of $500M USD. Philip initially joined Cochlear in the UK as the European Sales and Marketing Director and was part of the global management team that developed the global cochlear implant business and increased the company share price from $5 to $50 over a five year period. Subsequently Philip was promoted to the VP Global Marketing position based in Sydney, Australia
Since raising capital and relist ~400m shares have been traded which is roughly 1.7 times the shares issued in the raise. Typically in these cases the early capital players are happy to take the 50-100% gains that have been on offer, as these holdings are distributed to tighter hands that believe in the story then the stock begins to really move. In similar situations RAP, SAS etc the churn has been around 2.5 times the raise before any large run has commenced. With that in mind we likely still need to turn over 100-200m shares if this is going to follow the pathway paved by others. Obviously the more promotion that management get out and do from here on the faster that we are likely to see the overhead resistance diminish.
In summary my approach here has been to identify that the factors for significant rerate exist, from here I will simply wait for the probable outcome which will hopefully see the bags being counted around November...
Expand
